Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
(Evidence remains largely preclinical/analytical for TB-500 itself.) How BPC-157 Works BPC-157 is a stable gastric pentadecapeptide with a broad pro-healing, cytoprotective profile observed mainly in preclinical models
How it works: JAK2/growth hormone receptor upregulation: BPC-157 increases growth hormone receptor expression in tendon fibroblasts, sensitizing tissue to healing signals and accelerating structural repair FAK-paxillin pathway activation: enhances fibroblast migration and collagen deposition through focal adhesion kinase signaling, directly supporting connective tissue regeneration eNOS-driven angiogenesis: upregulates endothelial nitric oxide synthase to promote new blood vessel formation, improving oxygen and nutrient delivery to hypovascular tissues like tendons and ligaments Anti-inflammatory modulation: suppresses pro-inflammatory cytokines while preserving the early inflammatory phase needed for tissue repair, reducing chronic inflammation without blunting healing Administration: Subcutaneous injection (most common)
Phase 2: Introduce AOD 9604 (weeks 5-8) Once tirzepatide is tolerated at the initial dose, add AOD 9604 at 250mcg daily
Hydroxocobalamin 20 mg/ml Injection Solution is a potent formulation used in the treatment of specific types of anemia, particularly those caused by folate deficiency such as megaloblastic anemia
